US Broker Ratings

IDEAYA Biosciences, Inc. (IDYA): Analyst Consensus Points to 86% Upside Potential

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) stands at the forefront of the precision medicine oncology sector, offering compelling prospects for investors looking to capitalize on the biotechnology industry’s potential. This South..

Celldex Therapeutics, Inc. (CLDX) Investor Outlook: Harnessing Biotech Potential with a 168% Upside

Celldex Therapeutics, Inc. (NASDAQ: CLDX) stands as a noteworthy entity in the biotechnology sector, offering substantial promise through its innovative therapeutic antibody developments aimed at addressing severe inflammatory, allergic, autoimmune,..

UFP Technologies, Inc. (UFPT) Investor Outlook: Exploring a Potential 37.45% Upside

UFP Technologies, Inc. (UFPT) stands out in the healthcare sector, particularly within the medical devices industry, as it continues to innovate in the creation of specialized solutions for medical and..

Vericel Corporation (VCEL) Stock Analysis: Evaluating a Promising 43% Potential Upside

Vericel Corporation (NASDAQ: VCEL) is capturing investor attention with its strong foothold in the biopharmaceutical sector, particularly in the niche markets of sports medicine and severe burn care. The Cambridge,..

Teladoc Health, Inc. (TDOC) Stock Analysis: Exploring a 30.92% Potential Upside

Investors interested in the healthcare sector’s digital transformation have likely heard of Teladoc Health, Inc. (TDOC), a pioneer in virtual healthcare services. Despite its recent challenges, Teladoc presents an intriguing..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Biotech Innovator Poised for 84% Potential Upside

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a cutting-edge player in the biotechnology sector, is making waves with its innovative approach to treating severe allergic reactions. Headquartered in San Diego, California, this..

CONMED Corporation (CNMD) Stock Analysis: Evaluating the 14% Potential Upside Amid Healthcare Growth

For those with a keen eye on the healthcare sector, CONMED Corporation (NASDAQ: CNMD) presents a compelling case worth attention. As a key player in the medical devices industry, CONMED..

Travere Therapeutics (TVTX): Analyst Consensus Highlights a Potential 114% Upside for Investors

Travere Therapeutics, Inc. (NASDAQ: TVTX), a biopharmaceutical company focused on addressing rare kidney and metabolic diseases, has garnered significant attention from investors, spurred by a compelling potential upside of 114.29%...

Progyny, Inc. (PGNY) Stock Analysis: Healthcare Innovator with 15% Potential Upside

Progyny, Inc. (NASDAQ: PGNY), a prominent player in the healthcare sector, specifically in healthcare plans, offers a remarkable investment opportunity for those keen on the burgeoning field of fertility and..

Clover Health Investments (CLOV) Stock Report: Analyzing a 62.76% Potential Upside for Investors

Clover Health Investments, Corp (NASDAQ: CLOV) is capturing the attention of investors with its significant potential upside of 62.76%, as indicated by analyst target prices. Specializing in providing Medicare Advantage..

Belite Bio, Inc (BLTE) Stock Analysis: Unpacking a 34% Upside with Strong Buy Ratings

Belite Bio, Inc (BLTE) is capturing the attention of investors in the biotechnology sector, driven by its promising drug development pipeline and a robust 34.33% potential upside according to analyst..

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis: A 34.91% Potential Upside in Healthcare Investment

Guardian Pharmacy Services, Inc. (GRDN), a pivotal player in the healthcare sector, is making waves in the medical care facilities industry with its innovative technology-enabled services designed for long-term health..

Centessa Pharmaceuticals (CNTA) Investor Outlook: Analyzing the 101% Potential Upside

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is making waves in the biotechnology sector with its ambitious pipeline and potential for significant growth. Headquartered in Altrincham, UK, Centessa is a clinical-stage company..

ICU Medical, Inc. (ICUI) Stock Analysis: Evaluating a Strong 43% Potential Upside for Investors

ICU Medical, Inc. (NASDAQ: ICUI), a prominent player in the healthcare sector, is renowned for its innovative medical instruments and supplies, particularly in infusion therapy, vascular access, and vital care...

CRISPR Therapeutics AG (CRSP) Investor Outlook: Unpacking the 35.78% Potential Upside

CRISPR Therapeutics AG (NASDAQ: CRSP), a pioneering force in the biotechnology sector, has been captivating investor interest with its revolutionary approach to gene editing. As a company based in Zug,..

Structure Therapeutics Inc. (GPCR) Stock Analysis: Unlocking a 351.77% Upside Potential in Biotechnology

Structure Therapeutics Inc. (NASDAQ: GPCR) is capturing investor attention with its substantial upside potential in the biotechnology sector. With a market capitalization of $965.47 million, this clinical-stage biopharmaceutical company is..

Adaptive Biotechnologies (ADPT) Stock Analysis: Unlocking a 25% Revenue Growth Potential in the Biotech Sector

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is capturing investor attention with its innovative approach to diagnostics and therapeutic solutions in the biotechnology industry. With a market capitalization of $1.66 billion, this..

Ardent Health, Inc. (ARDT) Stock Analysis: Evaluating a 96% Potential Upside

Ardent Health, Inc. (NYSE: ARDT) is a noteworthy player in the healthcare sector, primarily operating within the medical care facilities industry. As a company that owns and manages a vast..

Evotec SE (EVO) Stock Analysis: Exploring a 53.85% Potential Upside in the Drug Discovery Sector

Evotec SE (EVO), a prominent player in the healthcare sector, specifically in the drug manufacturing industry, offers intriguing opportunities for investors despite its current financial challenges. Headquartered in Hamburg, Germany,..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Unveiling a 23.87% Potential Upside for Investors

LeMaitre Vascular, Inc. (LMAT), a key player in the medical instruments and supplies industry, presents an intriguing opportunity for investors with its promising potential upside of 23.87%. As a company..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds